Oncología y Atención del Cáncer

Sobre Oncología y Atención del Cáncer

China is the global second-largest oncology care destination by patient volume, with 50+ National Cancer Centers and Tier-3A oncology departments offering FDA-aligned, NMPA-approved treatment at 30-70% lower cost than the United States. International patients access the full spectrum — surgical oncology, radiation therapy (proton, IMRT, IGRT), targeted therapy, PD-1/PD-L1 immunotherapy, CAR-T cell therapy, and clinical trials — through SSAnkang's coordinator network at top-ranking hospitals across Beijing, Shanghai, Guangzhou, Tianjin, and Chengdu. Surgical oncology covers thoracic (lung, esophagus, mediastinum), gastrointestinal (gastric, colorectal, hepatobiliary, pancreatic), breast, gynecologic, urologic, head-neck, and orthopedic tumors. Robotic platforms (da Vinci) are widely available, with leading centers performing 1,000+ robotic cases per year. Laparoscopic and minimally-invasive approaches are now standard for most curative resections. China's radiation oncology infrastructure includes 8 active proton therapy centers (Shanghai, Beijing, Hefei, Guangzhou, others) — among the highest concentrations globally outside the US and Japan. IMRT, IGRT, SBRT and brachytherapy are universally available at Grade-3A centers. The Cancer Center proton facilities are accessible to international patients with pediatric, head-neck, and prostate tumors at $30,000-$50,000 per course (vs $100,000+ US). Pharmacologic oncology in China provides access to the full FDA-approved arsenal: Keytruda (pembrolizumab), Opdivo (nivolumab), and 12+ domestic Chinese PD-1 antibodies (Tyvyt/Sintilimab, Tislelizumab, Toripalimab, Camrelizumab) — typically 50-70% cheaper than imported equivalents. Targeted therapies (osimertinib, lorlatinib, alectinib for lung; trastuzumab, pertuzumab for breast; encorafenib for melanoma) and CAR-T cell therapies (Yescarta, Carvykti, Relmacabtagene) are accessible at major academic centers. International patients are coordinated end-to-end by SSAnkang: pathology re-review by Chinese oncologist (free pre-trip), NMPA-indication confirmation, hospital match by tumor type and oncologist availability, embassy invitation letter for medical visa, ground transfer, on-site bilingual case manager during treatment, and post-discharge handoff. Service tiers — Basic (free coordination), Gold ($599 full concierge), Diamond ($2,499 VIP with senior oncologist access). Contact yuhua0095@gmail.com; a feasibility report with recommended treatment, hospital, total course cost estimate, and visa support is delivered within 48 hours.